TriangleNCT00334282 · OUTCOME
Adjusted Mean Change From Baseline in the Visual Analog Scale (VAS) Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- points on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and Weeks 6, 12, 18, 24, and 48
What was measured
The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index) and a VAS score (VAS), obtained from participant's self-reports of their health on a VAS thermometer scale. The EQ-5D VAS ranges from 0% (worst imaginable health state) to 100% (best imaginable health state).
Analysis population: Participants in the ITT Population who completed HRQOL assessments at Baseline and had at least one post-Baseline assessment are included. Only participants who were on treatment at the given time point were asked to complete the questionnaire, and only those who completed the questionnaire could be analyzed for each individual time point.
Groups in this outcome
Pazopanib 800 mg
Pazopanib 800 mg (tablets) administered orally once a day
Placebo
Matching placebo administered orally once a day
| Group | Source count |
|---|---|
| Pazopanib 800 mg | 239 |
| Placebo | 111 |
Reported measurements
Week 12, n=212, 80
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib 800 mg | -0.9 | 21.07 | Not reported | Not reported | Not reported |
| Placebo | -3.6 | 23.04 | Not reported | Not reported | Not reported |
Week 6, n=239, 111
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib 800 mg | 0.4 | 22.55 | Not reported | Not reported | Not reported |
| Placebo | 0.2 | 25.35 | Not reported | Not reported | Not reported |
Week 18, n=189, 60
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib 800 mg | 0.1 | 23.20 | Not reported | Not reported | Not reported |
| Placebo | 0.1 | 19.35 | Not reported | Not reported | Not reported |
Week 24, n=161, 49
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib 800 mg | 2.6 | 22.16 | Not reported | Not reported | Not reported |
| Placebo | 5.4 | 21.27 | Not reported | Not reported | Not reported |
Week 36, n=95, 23
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib 800 mg | 2.4 | 24.21 | Not reported | Not reported | Not reported |
| Placebo | 8.8 | 23.96 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 21.07
- value
- -0.9
- group Id
- OG001
- spread
- 23.04
- value
- -3.6
- title
- Week 12, n=212, 80
- categories
- measurements
- group Id
- OG000
- spread
- 22.55
- value
- 0.4
- group Id
- OG001
- spread
- 25.35
- value
- 0.2
- title
- Week 6, n=239, 111
- categories
- measurements
- group Id
- OG000
- spread
- 23.20
- value
- 0.1
- group Id
- OG001
- spread
- 19.35
- value
- 0.1
- title
- Week 18, n=189, 60
- categories
- measurements
- group Id
- OG000
- spread
- 22.16
- value
- 2.6
- group Id
- OG001
- spread
- 21.27
- value
- 5.4
- title
- Week 24, n=161, 49
- categories
- measurements
- group Id
- OG000
- spread
- 24.21
- value
- 2.4
- group Id
- OG001
- spread
- 23.96
- value
- 8.8
- title
- Week 36, n=95, 23
- denoms
- counts
- group Id
- OG000
- value
- 239
- group Id
- OG001
- value
- 111
- units
- Participants
- description
- The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index) and a VAS score (VAS), obtained from participant's self-reports of their health on a VAS thermometer scale. The EQ-5D VAS ranges from 0% (worst imaginable health state) to 100% (best imaginable health state).
- dispersion Type
- Standard Deviation
- groups
- description
- Pazopanib 800 mg (tablets) administered orally once a day
- id
- OG000
- title
- Pazopanib 800 mg
- description
- Matching placebo administered orally once a day
- id
- OG001
- title
- Placebo
- param Type
- MEAN
- population Description
- Participants in the ITT Population who completed HRQOL assessments at Baseline and had at least one post-Baseline assessment are included. Only participants who were on treatment at the given time point were asked to complete the questionnaire, and only those who completed the questionnaire could be analyzed for each individual time point.
- reporting Status
- POSTED
- time Frame
- Baseline and Weeks 6, 12, 18, 24, and 48
- title
- Adjusted Mean Change From Baseline in the Visual Analog Scale (VAS) Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48
- type
- SECONDARY
- unit Of Measure
- points on a scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice